These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19261605)

  • 1. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38.
    Kamenecka T; Habel J; Duckett D; Chen W; Ling YY; Frackowiak B; Jiang R; Shin Y; Song X; LoGrasso P
    J Biol Chem; 2009 May; 284(19):12853-61. PubMed ID: 19261605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.
    Zheng K; Iqbal S; Hernandez P; Park H; LoGrasso PV; Feng Y
    J Med Chem; 2014 Dec; 57(23):10013-30. PubMed ID: 25393557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
    Ember B; Kamenecka T; LoGrasso P
    Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
    Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
    Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
    Scapin G; Patel SB; Lisnock J; Becker JW; LoGrasso PV
    Chem Biol; 2003 Aug; 10(8):705-12. PubMed ID: 12954329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold.
    Graczyk PP; Khan A; Bhatia GS; Palmer V; Medland D; Numata H; Oinuma H; Catchick J; Dunne A; Ellis M; Smales C; Whitfield J; Neame SJ; Shah B; Wilton D; Morgan L; Patel T; Chung R; Desmond H; Staddon JM; Sato N; Inoue A
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4666-70. PubMed ID: 16153829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3.
    Goettert M; Luik S; Graeser R; Laufer SA
    J Pharm Biomed Anal; 2011 Apr; 55(1):236-40. PubMed ID: 21316174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1
    Oh Y; Jang M; Cho H; Yang S; Im D; Moon H; Hah JM
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):372-376. PubMed ID: 31856610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury.
    Pirianov G; Brywe KG; Mallard C; Edwards AD; Flavell RA; Hagberg H; Mehmet H
    J Cereb Blood Flow Metab; 2007 May; 27(5):1022-32. PubMed ID: 17063149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Xue Y; Arzel E; Kallin E; Magnus A; Plobeck N; Viklund J
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1397-401. PubMed ID: 16337120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
    Dou X; Huang H; Jiang L; Zhu G; Jin H; Jiao N; Zhang L; Liu Z; Zhang L
    Eur J Med Chem; 2020 Sep; 201():112445. PubMed ID: 32603981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and optimization of a non-radioactive JNK3 assay.
    Peifer C; Luik S; Thuma S; Herweh Y; Laufer S
    Comb Chem High Throughput Screen; 2006 Sep; 9(8):613-8. PubMed ID: 17017881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors.
    Peifer C; Kinkel K; Abadleh M; Schollmeyer D; Laufer S
    J Med Chem; 2007 Mar; 50(6):1213-21. PubMed ID: 17323937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.
    Cao J; Gao H; Bemis G; Salituro F; Ledeboer M; Harrington E; Wilke S; Taslimi P; Pazhanisamy S; Xie X; Jacobs M; Green J
    Bioorg Med Chem Lett; 2009 May; 19(10):2891-5. PubMed ID: 19361991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis.
    Xie X; Gu Y; Fox T; Coll JT; Fleming MA; Markland W; Caron PR; Wilson KP; Su MS
    Structure; 1998 Aug; 6(8):983-91. PubMed ID: 9739089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
    Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in activation of ERK1/2 and p38 kinase in Jnk3 null mice following KA treatment.
    de Lemos L; Junyent F; Verdaguer E; Folch J; Romero R; Pallàs M; Ferrer I; Auladell C; Camins A
    J Neurochem; 2010 Sep; 114(5):1315-22. PubMed ID: 20534003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of activating transcription factor 2 by p38 MAP kinase during apoptosis induced by human amylin in cultured pancreatic beta-cells.
    Zhang S; Liu H; Liu J; Tse CA; Dragunow M; Cooper GJ
    FEBS J; 2006 Aug; 273(16):3779-91. PubMed ID: 16869889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.